Peptide

Enterome Announces Upcoming Presentation on OncoMimics™ Approach to Cancer Immunotherapy at the AACR Annual Meeting 2024

Retrieved on: 
Wednesday, March 6, 2024
Neoplasm, Research, Weill Cornell Medicine, AACR, Inflammation, Drug discovery, Peptide, Service provider, Poster, Cancer research, Vaccine

The poster will be presented by Dr. Vincent Panneton, Postdoctoral Associate in Pharmacology at the Ludwig Collaborative Laboratory led by Dr. Taha Merghoub and Dr. Jedd Wolchok at Weill Cornell Medicine.

Key Points: 
  • The poster will be presented by Dr. Vincent Panneton, Postdoctoral Associate in Pharmacology at the Ludwig Collaborative Laboratory led by Dr. Taha Merghoub and Dr. Jedd Wolchok at Weill Cornell Medicine.
  • “We are pleased to announce the presentation of these promising preclinical data which provide novel insights into the design of OncoMimics™ peptides for both neoantigens and tumor-associated antigens.
  • These results serve as an early validation of our approach to novel cancer immunotherapies,” said Laurent Chêne, Head of Drug Discovery at Enterome.
  • The abstract will be published in an online supplement to Cancer Research, the official journal of the American Association for Cancer Research, on March 22nd, and the poster will be available on Enterome’s website after the AACR Meeting.

Malibu shines a light on CLINUVEL’s pioneering work in photomedicine

Retrieved on: 
Tuesday, March 5, 2024
Skin cancer, EPP, Pigment, Nervous system, Attacca Quartet, Growth, XP, Skin, Xeroderma pigmentosum, Global health, Life, Parker, Risk, Health, Vitiligo, Peptide, Melanocortin, Patient, Medicine, Knowledge, Research, Brain, Pharmaceutical industry

The Group’s CEO Dr. Philippe Wolgen also unveiled what is next for the most exciting biopharmaceutical firm in the field of photomedicine today.

Key Points: 
  • The Group’s CEO Dr. Philippe Wolgen also unveiled what is next for the most exciting biopharmaceutical firm in the field of photomedicine today.
  • Philanthropy is central to the work of Lady Gaga and Michael Polansky, Sean Parker and Alexandra Parker.
  • At the event in Malibu, CLINUVEL announced the Photomedicine Foundation, which will count Mr Polansky as a trustee.
  • CLINUVEL is grateful to have their support as we translate our pharmaceutical technology into PhotoCosmetics and give back to underserved communities.

Hydreight Partners with Ola Digital Health, an Independent, National Pharmacy Network to Provide Health and Wellness Services in Store

Retrieved on: 
Monday, February 26, 2024
Acquisition, Pharmacy, Digital health, Growth, Pharmacist, Practitioner, Health, Peptide, LAS, NAD, Nursing, Ecosystem, Patient, Partnership, Hospital

VANCOUVER, British Columbia and LAS VEGAS, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV:NURS)(OTCQB:HYDTF)(FSE:S06) a mobile clinical network and medical platform which enables flexible, at-home medical services across 50 states in the United States, is very pleased to announce that it has entered into a partnership with Ola Digital Health (“Ola”) an innovative healthcare platform with a national pharmacy network in the United States, to provide health and wellness services inside its network of brick and mortar locations.

Key Points: 
  • Ola Digital Health is an innovative healthcare company with a network of 300 independent retail pharmacies in the United States.
  • Hydreight will be the health and wellness service provider in seven pharmacy locations as part of Phase I rollout, starting in February 2024.
  • Based on the success of Phase I, Ola will leverage its 300-pharmacy network to utilize these services.
  • Hydreight will leverage its proprietary healthtech platform, doctor and nurse network, and pharmacy distribution to provide its services to patients within the brick-and-mortar locations.

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

Retrieved on: 
Wednesday, February 21, 2024
Fiscal, Investment, FDA, See, Growth, Covenant, Pharmacy, Calendar, HFS, Exercise, Government, Annual report, Symantec Endpoint Protection, Weakness, Audit, Indian stock exchange, GAAP, History, Peptide, Element, Classification, Patient, Policy, Uncertainty, Corporation, Liquidity, HIV, Depreciation, Security (finance)

For the fourth quarter of Fiscal 2023, sales of EGRIFTA SV® reached $16,958,000 compared to $14,458,000 in the fourth quarter of the prior year, representing an increase of 17.3%.

Key Points: 
  • For the fourth quarter of Fiscal 2023, sales of EGRIFTA SV® reached $16,958,000 compared to $14,458,000 in the fourth quarter of the prior year, representing an increase of 17.3%.
  • In the fourth quarter of Fiscal 2023, Trogarzo® sales amounted to $6,494,000 compared to $6,963,000 for the same quarter of Fiscal 2022, representing a decrease of 6.7%.
  • Lower unit sales in the fourth quarter of Fiscal 2023, were also a result of higher inventory buildup in Fiscal 2022, a situation which has resolved itself in Fiscal 2023.
  • Net finance costs in the fourth quarter of Fiscal 2022 included interest on the Convertible Notes, whereas this amount was nil in the fourth quarter of Fiscal 2023.

Pyramid Labs Appoints Dirk Lange as CEO and Announces a Doubling of Commercial Fill-Finish Capacity

Retrieved on: 
Wednesday, March 6, 2024
Other Manufacturing, Professional Services, Manufacturing, Biotechnology, Health, Pharmaceutical, Retail, Asset Management, Supply Chain Management, Multimedia, Growth, Nucleotide, CDMO, Peptide, Pyramid, Protein, Knowledge, Audax, Management

View the full release here: https://www.businesswire.com/news/home/20240306544414/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240306544414/en/
    “I am excited to lead Pyramid during this pivotal time in the Company’s growth trajectory and as the company is doubling its commercial fill-finish capacity,” noted Dirk Lange.
  • Lange most recently led MilliporeSigma’s Life Science Services business and previously was the CEO of KBI Biopharma and Selexis.
  • He joins Pyramid at a point of accelerated growth, as the company is doubling its commercial fill-finish capacity.
  • “We are very pleased to welcome Dirk to the Pyramid team as we continue in our transformative growth phase,” commented Medhat Gorgy.

Argonaut Manufacturing Services Expands Aseptic Pharmaceutical Fill / Finish Capabilities with $45 Million Equity Investment from NewVale Capital and Telegraph Hill Partners

Retrieved on: 
Tuesday, March 5, 2024
Packaging, Health, Manufacturing, Other Manufacturing, Pharmaceutical, Biotechnology, ISO, FDA, RBC Capital Markets, Syringe, CFR, Peptide, PMDA, Certification, Patient, Protein, Oligonucleotide

Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, announced today the completion of a $45 million financing to support its new drug product fill / finish expansion.

Key Points: 
  • Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, announced today the completion of a $45 million financing to support its new drug product fill / finish expansion.
  • Argonaut expects to have fully validated the facility and all equipment in 2025.
  • The financing was led by NewVale Capital, a growth equity fund focused on innovative pharmaceutical and life science services businesses, with participation from existing majority investor Telegraph Hill Partners, and other current investors.
  • “For years, small- and medium-sized biopharma companies have struggled to find reliable, high-quality fill / finish capabilities from providers that prioritize their molecules.

Global Bicycle Toxin Conjugates Clinical Trials Insight 2024 - Bicycle Therapeutics Emerges as a Trailblazer, Leading the Novel Development of Bicycle Toxin Conjugates for Cancer Therapy - ResearchAndMarkets.com

Retrieved on: 
Monday, March 4, 2024
Pharmaceutical, Health, Oncology, Therapy, Research, Indication, Hope, Peptide, Medicine, Patient, Cell death, Cancer, Pharmaceutical industry

The "Global Bicycle Toxin Conjugates Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bicycle Toxin Conjugates Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • Bicycle toxin conjugates, which are a seamless combination of bicyclic peptides and potent cytotoxic drugs, are at the forefront of therapeutics development.
  • Bicycle Therapeutics emerges as a trailblazer, leading the novel development of bicycle toxin conjugates for cancer therapy.
  • Global Bicycle Toxin Conjugates Clinical Trials & Market Opportunity Insight 2024 Report Highlights:
    Clinical Research & Market Trends by Region: US, UK & EU
    Comprehensive Insight on All Drugs in the Clinical Pipeline by Company, Indication & Phase

New Fortress Energy Places Terminal Gas Sul LNG Terminal in Santa Catarina, Brazil into Operation

Retrieved on: 
Friday, March 1, 2024
Other Energy, Maritime, Utilities, Logistics, Supply Chain Management, Oil, Gas, Transport, Energy, FSRU, TGS, Arno Drescher, Wes Edens, Peptide

New Fortress Energy, Inc. (Nasdaq: NFE) (“NFE” or the “Company”) today announced that its Terminal Gas Sul (“TGS”) LNG terminal located in Santa Catarina, Brazil, is now operational with the Energos Winter Floating Storage Regasification Unit (FSRU) on-site.

Key Points: 
  • New Fortress Energy, Inc. (Nasdaq: NFE) (“NFE” or the “Company”) today announced that its Terminal Gas Sul (“TGS”) LNG terminal located in Santa Catarina, Brazil, is now operational with the Energos Winter Floating Storage Regasification Unit (FSRU) on-site.
  • TGS is an offshore LNG import terminal with a capacity of approximately 6 MTPA (300 TBtu) and maximum send out of 500 mmscf/day.
  • The terminal includes the Winter FSRU and a 33-kilometer, 20-inch pipeline, which connects the facility to the existing inland Transportadora Brasileira Gasoduto Bolívia-Brasil (“TBG”) pipeline.
  • The TGS terminal is essential infrastructure and will play a vital role in meeting the region's power and gas requirements.

Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model

Retrieved on: 
Wednesday, February 28, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Acquisition, Neuropharmacology, Morris water navigation task, Dementia, Neuroscience, MWM, Amnesia, IGC, Spatial navigation, Deficit spending, Peptide, Memory, Spatial memory, Patient, LTP, Agitation, Mouse

The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.

Key Points: 
  • The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.
  • Ram Mukunda, CEO, commented, "These results underscore the efficacy of TGR-63 in enhancing spatial memory function in an Alzheimer's disease model, offering promising implications for potential therapeutic interventions in Alzheimer's and related neurodegenerative conditions.
  • The improvements in memory acquisition, consolidation, spatial memory formation, and retrieval highlight its potential in addressing cognitive impairment in Alzheimer's Disease.
  • The NOR Test, a cornerstone of preclinical research, evaluates recognition memory, a component of declarative memory responsible for recognizing previously encountered stimuli.

Cheniere Partners Reports Fourth Quarter and Full Year 2023 Results and Introduces Full Year 2024 Distribution Guidance

Retrieved on: 
Thursday, February 22, 2024
Oil, Gas, Energy, IPM, Natural gas, British thermal unit, Sale, Federal Energy Regulatory Commission, Line of credit, SPL, Public expenditure, Hand, Peptide, FERC

In November 2023, SPL redeemed $50 million in principal amount of the 2024 SPL Senior Notes with cash on hand.

Key Points: 
  • In November 2023, SPL redeemed $50 million in principal amount of the 2024 SPL Senior Notes with cash on hand.
  • The common unit distribution and the related general partner distribution will be paid on February 14, 2024.
  • Cheniere Energy, Inc. will host a conference call to discuss its financial and operating results for fourth quarter and full year 2023 on Thursday, February 22, 2024, at 11 a.m. Eastern time / 10 a.m. Central time.
  • The call and accompanying slide presentation will include financial and operating results or other information regarding Cheniere Partners.